Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Status:
Terminated
Trial end date:
2017-09-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if GTx-024 is effective and safe in the treatment
of patients with advanced, androgen receptor positive triple negative breast cancer (AR+
TNBC).